- FTSE 100 index adds 48 points
- BT to keep Huawei equipment for emergency services network
- UK June CPI rises 0.6%
10.50am: BT to keep Huawei technology for emergency services network
The Footsie added a few more points in mid-morning, rising 48 points to 6,227.
However, it was revealed it will keep using Huawei technology for emergency services.
The telecoms firm is building a £9bn network for 300,000 frontline users, including the police, fire and ambulance services, The Times reported.
It will handle sensitive information, such as sharing patient data between emergency vehicle and hospitals, add extra radio frequencies in rural areas and over 400 new mast sites.
The FTSE 100-listed firm said two years ago it would remove Huawei equipment from the core of the network but it would remain in elements such as masts and antennas.
It is though removing parts made by the Chinese giant from its existing mobile network, as well as excluding them from the 5G network under construction.
9.55am: Moderna confirms positive results on early-stage trials for COVID-19 vaccine
FTSE 100 trimmed its gains in mid-morning, rising 31 points to 6,211, while sterling was 0.4% higher at US$1.2608.
In the US, (NASDAQ:MRNA) shot up 18% to US$88.66 in premarket trading after confirming positive results on its COVID-19 vaccine candidate, following preliminary data shared in May.
The jab was safe and built an immune response in all 45 participants of the first phase of clinical trials.
A fifth of the participants reported one or more severe adverse effects at a the 250 µg dose level, while the 100 µg one caused effects which were transient and mild or moderate in severity.
The biotech firm has now completed the enrolment of 300 healthy adults aged 18-55 and another 300 above 55 for the second phase of trials, while the final phase will involve 30,000 participants in the US.
The company has produced enough doses for the trials and remains on track to deliver 500mln and potentially up to 1bn jabs per year, beginning in 2021.
“Like with every vaccine update, the fact these are only baby steps when considering the time line of clearance, mass production and implementation didnt stop investors buying into the optimism,” Connor Campbell, an analyst at Spreadex, noted.
8.50am: Footsie pushes ahead
The FTSE 100 took its cue from a buoyant Wall Street and Asias main markets to kick off Wednesday firmly in positive territory.
In early trade, the index of UK blue-chips advanced 54 points to 6,233.40.
Another batch of economic data – this time June inflation – added little in the way of real insights as to the health of the British economy.
The cost price measure came in at 0.6%, up from 0.5% in May, with lockdown demand for clothing and video games supporting the modest upward momentum.
Economics wonks at the EY ITEM Club expect inflation to “rise gradually during 2021 as the recovery gains traction”, reaching 2% by the end of next year.
Leading the fallers with a decline of 4.7% was Burberry (LON:BRBY), which warned of the lingering impact of the coronavirus while presiding over a 45% first-quarter sales decline.
“The duration of a return to normality remains largely unknown and ongoing political tensions in the Asian region are still a concern,” said Richard Hunter, analyst at Interactive Investor.
“Despite the recovery of the shares since the March nadir, the performance over the last year reflects these concerns, with the shares having dropped 22% in that period, as compared to a decline of 18% for the wider FTSE100. The market consensus of the shares has recently deteriorated slightly to come in at a weak hold, and even though Burberry is playing to its strengths as far as possible, the environment remains gruelling.”
Among the small-caps, two members of the life sciences sector showed themselves to be coronavirus resistant, weighing in with strong end-of-period trading statements.
Allergy Therapeutics (LON:AGY), up 7.7%, said its earnings would exceed expectations, while cell engineering specialist MaxCyte (LON:MXCT), was up 6.7% after seeing first-half revenues soar by just under a third.
Proactive news headlines:
Allergy Therapeutics PLC (LON:AGY) has said its earnings are likely to exceed expectations after a strong year. Net revenues for the 12 months ended June 30, 2020, were £78.2mln, up 6%, it said, while the firm was in a strong financial position with £37mln in the bank at the period end. The performance of the group, which develops and sells short course allergy inoculations, was particularly impressive given the challenges in the closing quarter of the year posed by the coronavirus (COVID-19) lockdown.
AFC Energy PLC (LON:AFC) is getting into the zero-emission motorsport business by teaming up with Extreme E, the team behind FIAs Formula E racing championship. Extreme E is planning a hydrogen-fuelled electric SUV rally racing series that is slated to launch in early 2021, and AIM-quoted AFC will provide off-grid power to the racing series – including its zero-emission charging system. The series is designed to be a practical and symbolic showcase with the off-road race events taking place in remote locations which, according to AFC, will highlight important climate issues and also show how hydrogen can be used as a viable alternative fuel all environments.
Bezant Resources PLC (LON:BZT) told investors that due diligence for its proposed acquisition of the Hope Gold project in Namibia is “progressing as anticipated” as it provided new details from ongoing technical work. The company, in a statement, noted historical drilling information that has come to light during due diligence which creates further excitement and confidence for the project. "This is an exciting potential project for the company and the more we dig into the archives, it becomes evident that resources quoted were the subject of extensive drilling programmes which gives us added confidence," Colin Bird, Bezant chief executive said in a statement. “It is also evident that the contribution of gold has been neglected which in today's times could in our view be quite significant.”
BATM Advanced Communications Limited (LON:BVC) has launched three new diagnostic kits which it said will “significantly advance” the diagnosis of coronavirus and other respiratory illnesses. The networking and medical laboratory systems group said one of the new kits is a serologic test, which has been upgraded to measure the quantity of antibodies in the blood rather than just their presence or absence. The second new kit is an upgraded antigen test to detect spike gene and enable the diagnosis of coronavirus in people with low viral loads, increasing testing accuracy. The final new kit is a molecular diagnostics test that has been developed to rapidly identify the specific respiratory virus or bacteria in someone presenting with symptoms of, or suspected to have pre-symptomatic respiratory illnesses. BATM said it expects to begin sale and production of the kits at its Adaltis facility in Italy at the end of the third and start of the fourth quarter of 2020.
Open Orphan PLC (LON:ORPH) said it has signed an option agreement to acquire a company called CHIMagents for a nominal sum. The business designs, manufactures, and tests agents for use in challenge studies, which complements the work carried out in the infectious diseases field by Open Orphan subsidiary hVIVO. CHIMagent's Adrian Wildfire, who has over 20 years of industry experience, will join hVIVO as a director. Open Orphan chief executive Cathal Friel said the option agreement was an “important strategic step as we rapidly grow our pipeline of challenge studies”.
MaxCyte PLC (LON:MXCT) said its revenues grew by 30% to US$10.9mln in the first half of 2020 and told investors that its research and development operation was expected to be self-funded by the end of the year. The company licences out its technology, which generates a revenue stream and potential milestone payment, currently worth an estimated US$800mln, from life sciences companies that use its cell engineering know-how in drug development. It has also begun advancing its own potential treatments, creating an R&D business called CARMA Cell Therapies.
Galileo Resources PLC (LON:GLR) has announced the appointments of two highly experienced and successful Kalahari Copper Belt exploration geologists, Dr Quinton Hills and Fred Nhiwatiwa as members of the company's senior management to provide assistance with its exploration projects in Botswana. The company noted that the new team members have previously discovered mineral deposits that have led to the development of mines in Botswana. Galileo said it will shortly commence a comprehensive and targeted exploration program utilising geochemical and geophysical techniques that have been routinely used to find copper-silver deposits in the Kalahari Copper Belt.
Anglo Asian Mining PLC (LON:AAZ) has reported that it raked in an extra US$3.2mln in cash in the second quarter of 2020. In the three months to June 30, 2020, the Azerbaijan-focused miner said its cash balance stood at US$29.2mln at the end of the period, while gold production in the quarter had come in at 12,048 ounces (oz) compared to 17,149 oz in the prior year. Anglo Asian said the lower figure was due to lower ore grades processed from its Gedabek open pit operation, which had been its efficiency impacted by the coronavirus pandemic, and less ore from the Gadir underground mine.
Woodbois Limited (LON:WBI), the African forestry and timber group, has raised £13.1mln from existing investors, retail investors – via the PrimaryBid platform – and institutions as part of a debt restructuring and refinancing. Through the debt restructuring, holders have agreed to convert 75% of US$30mln of outstanding convertible bonds into new ordinary shares and new non-voting shares. The new shares were issued at 2p, a 43% discount to the close last night. In a statement, Woodbois said the fundraise and debt restructuring will position the company to grow its timber production and trading activities rapidly.
Kodal Minerals PLC (LON:KOD), the mineral exploration and development company focused on its Bougouni Lithium Project in southern Mali, said it has secured sufficient funding resources to accelerate completion of the next phases of its development projects and to evaluate exciting new opportunities via a US$1.5mln unsecured convertible loan agreement with Riverfort Global Opportunities PCC and YA II PN Ltd. It said the £1.5mln loan agreement, with an initial advance of US$750,000, will have a 15-month term and carry interest at a rate of 9.85% per annum payable monthly. The investors will have the option to convert outstanding principal and interest into new ordinary shares in the company. Kodal can repay the loan at any time in cash, and the investors will also be issued with warrants exercisable into ordinary shares in the company at a premium to the current share price.
Feedback PLC (LON:FDBK) has announced the appointment of Philipp Prince as a new independent non-executive director, effective immediately. It noted that Prince is a chartered accountant with extensive experience in senior finance roles in both private and listed technology companies and runs his own financial consultancy business, is a board adviser at Overmore Limited, a marketing technology firm, and recently joined BCB Group Holdings Limited, a financial services challenger, as its non-board CFO. He was previously the CFO of Defenx PLC, an AIM-listed mobile cybersecurity company, where he managed the IPO process, fundraising and investor relations and Interim CFO at Enecsys PLC, a private equity-backed solar micro-inverter developer. For over 20 years, Philipp worked at BDO LLP, where he was a corporate finance partner from 2002-2013. Rory Shaw, chairman of Feedback, commented: "Philipp has strong experience within the technology sector, especially fundraising, capital markets and M&A. His input will be invaluable as we look to deliver shareholder value with the rollout of Bleepa to the NHS and other healthcare providers."
e-therapeutics PLC (LON:ETX) has announced that further to the fundraise it announced on July 7, 2020, Numis Securities has exercised the broker option in respect of 2,875,000 new ordinary shares raising gross proceeds of approximately £0.35mln for the company. The broker option shares are being issued at a price of 12p per share, being the placing price and will be issued on the same terms and conditions as placing shares. With the completion of the broker option, the company said it can confirm that a total of £11.6mln in gross proceeds has been raised; comprising of a firm placing of £6.3mln, a share subscription of £2.8mln, a retail offer via the PrimaryBid platform of £750,000 and £1.69mln via the broker option.
Greatland Gold PLC (LON:GGP), the precious and base metals exploration and development company, said it has received notice from Numis Securities that it is closing its natural resources division. As a result, Numis will cease to act as joint broker to the company with immediate effect. The company added that is in advanced discussions to appoint a new joint broker to focus on further growing Greatland's institutional investor shareholder base, in the meantime, SI Capital is sole broker to tRead More – Source